CD274 and Merkel cell skin cancer: The two main trials to date testing novel immunotherapy agents (anti‐PDL‐1 avelumab and anti PD‐1 pembrolizumab)13, 19 included only a small number of participants and excluded patients with preexisting immune suppression, a known risk factor for MCC.